<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="7206"><DrugName>heparin-EGF-like factor, Scios Nova</DrugName><DrugSynonyms><Name><Value>HB-EGF, Scios Nova</Value></Name><Name><Value>heparin-EGF-like factor, Scios Nova</Value></Name></DrugSynonyms><CompanyOriginator id="19831">Scios Inc</CompanyOriginator><CompaniesSecondary><Company id="19831">Scios Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="19831" type="Company"><TargetEntity id="4295907891" type="organizationId">Scios LLC</TargetEntity></SourceEntity><SourceEntity id="129" type="ciIndication"><TargetEntity id="10017944" type="MEDDRA"></TargetEntity><TargetEntity id="D005767" type="MeSH"></TargetEntity><TargetEntity id="-728854171" type="omicsDisease"></TargetEntity><TargetEntity id="369" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="337" type="ciIndication"><TargetEntity id="K51" type="ICD10"></TargetEntity><TargetEntity id="10009900" type="MEDDRA"></TargetEntity><TargetEntity id="D003093" type="MeSH"></TargetEntity><TargetEntity id="-1993209976" type="omicsDisease"></TargetEntity><TargetEntity id="396" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="711" type="ciIndication"><TargetEntity id="J98.9" type="ICD10"></TargetEntity><TargetEntity id="10038683" type="MEDDRA"></TargetEntity><TargetEntity id="D012140" type="MeSH"></TargetEntity><TargetEntity id="-2143937119" type="omicsDisease"></TargetEntity><TargetEntity id="269" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="PTGT-00682" type="ciTarget"><TargetEntity id="201985772919563" type="siTarget">Epidermal growth factor receptor</TargetEntity><TargetEntity id="233" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="129">Gastrointestinal disease</Indication><Indication id="337">Ulcerative colitis</Indication><Indication id="711">Respiratory disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="662">Epidermal growth factor receptor agonist</Action></ActionsPrimary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology></Technologies><LastModificationDate>2017-09-02T10:54:18.000Z</LastModificationDate><ChangeDateLast>2003-04-30T13:31:38.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;HB-EGF is a heparin-EGF-like growth factor which was under investigation by Scios Nova as a potential treatment for gastrointestinal disease, ulcerative colitis and respiratory disorders [&lt;ulink linkID="156850" linkType="reference"&gt;156850&lt;/ulink&gt;]. No development had been reported since 1991, however, and in February 2000, a company spokesperson confirmed that the program has been terminated [&lt;ulink linkID="357450" linkType="reference"&gt;357450&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19831">Scios Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="337">Ulcerative colitis</Indication><StatusDate>2000-02-29T00:00:00.000Z</StatusDate><Source id="357450" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19831">Scios Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="129">Gastrointestinal disease</Indication><StatusDate>2000-02-29T00:00:00.000Z</StatusDate><Source id="357450" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19831">Scios Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="711">Respiratory disease</Indication><StatusDate>2000-02-29T00:00:00.000Z</StatusDate><Source id="357450" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19831">Scios Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="711">Respiratory disease</Indication><StatusDate>1998-02-12T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19831">Scios Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="129">Gastrointestinal disease</Indication><StatusDate>1998-02-12T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19831">Scios Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication><StatusDate>1998-02-12T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19831">Scios Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="711">Respiratory disease</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19831">Scios Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="129">Gastrointestinal disease</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19831">Scios Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="337">Ulcerative colitis</Indication></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00682"><Name>Epidermal growth factor receptor</Name><SwissprotNumbers><Swissprot>P00533</Swissprot><Swissprot>P04412</Swissprot><Swissprot>P13387</Swissprot><Swissprot>P55245</Swissprot><Swissprot>Q01279</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="985722" number="WO-00013710" title="Hydrogel compositions for the controlled release administration of growth factors"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>